Pathology startups route their models through a rival marketplace
Two of digital pathology’s better-known AI developers have decided that distribution beats exclusivity. Aiforia has signed a commercial agreement putting its cancer-detection models inside PathAI’s AISight Marketplace.
The deal lets laboratories already running PathAI’s AISight Dx image management system add Aiforia’s algorithms without rebuilding their case-review workflow. Aiforia said the agreement carries a particular focus on widening its US footprint, where the Finnish company is less established than in Europe.
The two firms occupy different rungs of the same ladder. PathAI sells the platform that hosts images and connects to laboratory and hospital IT systems, along with its own tools for biomarker quantification and tissue classification. Aiforia sells specific diagnostic models, several carrying CE-IVD marks for European clinical use.
Neither company disclosed how many laboratories the integration reaches or what revenue it might produce. That silence matters, because marketplace arrangements in pathology have so far generated more announcements than disclosed adoption.
Jukka Tapaninen, Aiforia’s chief executive, framed the deal as access to pathologists who already work inside PathAI’s system. Nick Brown, PathAI’s chief growth officer, cast it as giving those pathologists a wider toolset in one place.
For hospital labs, the practical appeal is procurement simplicity. Adding a validated algorithm to an existing viewer is a lighter lift than standing up a second vendor platform, a real constraint for departments without dedicated informatics staff.
Aiforia separately won Finland’s Digital Innovation of the Year 2026 public vote in the enterprise category for its cancer diagnostic software.
